SCHEMBL6715023

SCHEMBL6715023

CC(C)(C)OC(=O)NN(C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1)C1CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.58
ABCC3 O15438 1/20 0.58
ABCC4 O15439 1/20 0.58
CACNA1F O60840 1/20 0.58
ABCB11 O95342 1/20 0.58
ABCB1 P08183 1/20 0.58
HTR1A P08908 1/20 0.58
DRD2 P14416 1/20 0.58
TACR2 P21452 1/20 0.58
TBXAS1 P24557 1/20 0.58
OPRM1 P35372 1/20 0.58
DRD3 P35462 1/20 0.58
AVPR1A P37288 1/20 0.58
OPRD1 P41143 1/20 0.58
OPRK1 P41145 1/20 0.58
HTR2B P41595 1/20 0.58
CACNA1D Q01668 1/20 0.58
SLC6A3 Q01959 1/20 0.58
KCNH2 Q12809 1/20 0.58
CACNA1S Q13698 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445230 0.90 CYP3A4 (0.57) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL6445233 0.90 CYP3A4 (0.57) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL6950150 0.89 CYP3A4 (0.45) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL6444048 0.87 CYP3A4 (0.54) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL6444044 0.87 CYP3A4 (0.54) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL6712827 0.86 CYP3A4 (0.53) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL8709404 0.84 CYP3A4 (0.57) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL8709400 0.84 CYP3A4 (0.57) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL6711001 0.83 CYP3A4 (0.52) CYP3A4ABCC3ABCC4CACNA1FABCB11
SCHEMBL6443042 0.81 CYP3A4 (0.58) CYP3A4ABCC3ABCC4CACNA1FABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266871-A1 Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons PHARMACIA & UPJOHN 2004-12-30 US disclosed
WO-1993018006-A1 AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUED HYDROCARBONS NARHEX LIMITED (HK) 1993-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266871-A1 Methods for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons BACE1, BACE2, PSEN1 CYP3A4 1862/4885ABCC3 2195/4885ABCC4 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.